Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review
Schizophrenia Research · 2026-06 · 292 · 69-78
DOI: 10.1016/j.schres.2026.03.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Schizophrenia Research, 2026-06. Verfasst von Michel Sabé und 26 weiteren Autor:innen. Beteiligte Einrichtung: Division of Addiction Psychiatry, Department of Psychiatry, University Hospitals of Geneva, 70, Grand-Pré, CH-1202, Geneva, Switzerland; Faculty of M…. Hauptthemen laut MEDLINE: Hallucinogens, Schizophrenia, Depression, Major Depressive Disorder. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS.
Themen: Depression
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Addiction Psychiatry, Department of Psychiatry, University Hospitals of Geneva, 70, Grand-Pré, CH-1202, Geneva, Switzerland; Faculty of Medicine, University of Geneva, Geneva, Switzerland; Division of Adult…
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
- Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA; Center for Novel Therapeutics in Addiction Psychiatry, Department of Psychiatry and Behavioral Sciences, University of Washin…
- Department of Clinical Psychology, School of Health Sciences, The University of Manchester, Manchester, UK.
- Psychedelic-Assisted Therapy Post-Graduate Program, Health Sciences and Human Services, Vancouver Island University, Nanaimo, BC, Canada.
- Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA, USA; VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
Förderung
- NIH HHS
Zitieren
APA
Sabé, M., Grof, P., Sackett, N. B., Tai, S., Kryskow, P., Bershad, A., Turkington, D., Buonarroti, M., De Pieri, M., Baniotopoulos, P., Eskinazi, M., Böge, K., Leucht, S., Seragnoli, F., Furtado, L., Brakha, T. A., Curtis, L., Kirschner, M., Kaiser, S., …, & La Torre, J. (2026). Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review. Schizophrenia Research, 292, 69-78. https://doi.org/10.1016/j.schres.2026.03.003
Vancouver
Sabé M, Grof P, Sackett NB, Tai S, Kryskow P, Bershad A, et al. Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review. Schizophrenia Research. 2026;292:69-78. doi:10.1016/j.schres.2026.03.003
BibTeX
@article{Sab2026,
author = {Sabé, Michel and Grof, Paul and Sackett, Nathan B and Tai, Sara and Kryskow, Pamela and Bershad, Anya and Turkington, Douglas and Buonarroti, Matteo and De Pieri, Marco and Baniotopoulos, Pantelis and Eskinazi, Mickael and Böge, Kerem and Leucht, Stefan and Seragnoli, Federico and Furtado, Léonice and Brakha, Tatiana Aboulafia and Curtis, Logos and Kirschner, Matthias and Kaiser, Stefan and Penzenstadler, Louise and Zullino, Daniele and Højlund, Mikkel and Gallo, Jade and Solmi, Marco and Sapienza, Jacopo and Bosia, Marta and La Torre, Joseph},
title = {Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review},
journal = {Schizophrenia Research},
year = {2026},
volume = {292},
pages = {69--78},
doi = {10.1016/j.schres.2026.03.003}
}
EUVIMED